Systemic sclerosis (SSc) was one of the major topics covered during the 2015 American College of Rheumatology meeting.
Selected abstracts related to basic research reported the identification of new relevant targets including interferon regulatory factor 7 (IRF7), long coding RNAs, C-terminal domain of endostatin, M2 macrophages and keratinocytes. Several new compounds, including abatacept, nintedanib and soluble guanylate cyclase stimulators, displayed potent antifibrotic effects in complementary animal models of experimental dermal fibrosis.
Clinical aspects of the disease were also largely covered, with a specific focus on cardiac biomarkers and the relationship between cancer and SSc. The results of several clinical trials were also presented, including the comparison between cyclophosphamide and mycophenolate mofetil in the scleroderma lung study-2 and the effects of riociguat in patients with pulmonary arterial hypertension associated with connective tissue diseases.
Get full access to this article
View all access options for this article.
References
1.
WuMSalazarGZhouXGuoXReveilleJDAgarwalSKet al.Interferon regulatory factor 7 (IRF7): the possible link between inflammation and fibrosis in SSc pathogenesis [abstract]. Arthritis Rheumatol2015;67(Suppl 10) Abstract 3131.
2.
PacheraEAssassiSSalazarGFrankBertoncelj MDobrotaRet al.Long noncoding h19x is a key mediator of Tgf-beta induced pro-fibrotic effects in the pathogenesis of systemic sclerosis and other fibrotic diseases [abstract]. Arthritis Rheumatol2015;67(Suppl 10) Abstract 2152.
3.
NishimotoTTakiharaTMlakarLSuYChambersRFeghali-BostwickCThe Anti-fibrotic effect of endostatin-derived peptide is mediated by the urokinase pathway via binding to enolase-1 and urokinase plasminogen activator receptor [abstract]. Arthritis Rheumatol2015;67(Suppl 10) Abstract 3133.
4.
SornasseTChenHRiceLStifanoGJahreisASiegelJet al.Inhibition of myeloid-associated gene expression in skin biopsy samples of systemic sclerosis patients treated with tocilizumab [abstract]. Arthritis Rheumatol2015;67(Suppl 10) Abstract 2151.
PonsoyeMFrantzCRuzehajiNElhaiMRuizBCauvetAet al.Treatment with abatacept prevents experimental dermal fibrosis and induces regression of established inflammation-driven fibrosis [abstract]. Arthritis Rheumatol2015;67(Suppl 10) Abstract 2150.
7.
HuangJBeyerCZhangYPalumbo-ZerrKDeesCDistlerOet al.Nintedanib ameliorates fibrotic and vascular manifestations in preclinical models of systemic sclerosis [abstract]. Arthritis Rheumatol2015;67(Suppl 10) Abstract 2153.
8.
SandnerPDeesCDistlerJHWBeyerCDistlerAZhangYet al.Stimulators of soluble guanylate cyclase (sGC) inhibit experimental skin fibrosis of different aetiologies [abstract]. Arthritis Rheumatol2015;67(Suppl 10) Abstract 1905.
9.
SandnerPBeyerCDistlerJHWHaasbachEStimulators of soluble guanylate cyclase (sgc) improve wound healing in the tsk-1 mouse skin fibrosis mode [abstract]. Arthritis Rheumatol2015;67(Suppl 10) Abstract 1906.
10.
De LucaGBoselloSLGabrielliFBerardiGparisiFRuccoMet al.Prognostic role of ventricular ectopic beats in systemic sclerosis [abstract]. Arthritis Rheumatol2015;67Suppl 10Abstract 3138.
11.
MeijsJde BoerBSchouffoerAHuizingaTWJPutterHde Vries-BouwstraJKThe influence of immunosuppressive therapy on microangiopathy in systemic sclerosis as measured with nailfoldcapillaroscopy [abstract]. Arthritis Rheumatol2015;67Suppl 10Abstract 3262.
12.
OzenGKorkmazFSunbulMDenizRTigenKAtagunduzPet al.Subclinical atherosclerosis and estimation of cardiovascular risk in systemic sclerosis [abstract]. Arthritis Rheumatol2015;67(Suppl 10) Abstract 825.
13.
AncutaCBelibouCPomirleanuCMihaiCAncutaICarreiraPEet al.Assessment of subclinical atherosclerosis in patients with systemic sclerosis: results from a multicentric cohort [abstract]. Arthritis Rheumatol2015;67(Suppl 10) Abstract 1903.
BoselloSLDe LucaGForniFDi MarioCparisiFCanestrariGet al.Prognostic cardiac disease biomarkers in patients with systemic sclerosis without pulmonary arterial hypertension [abstract]. Arthritis Rheumatol2015;67(Suppl 10) Abstract 847.
16.
SugiyamaKKobayashiHKobayashiYNagasawaYIkumiNNozakiTet al.Association of myocardial abnormalities with disease characteristic and brain natriuretic peptide (bnp) in systemic sclerosis without cardiac symptoms as assessed using cardiac magnetic resonance imaging; a prospective multicenter study [abstract]. Arthritis Rheumatol2015;67(Suppl 10) Abstract 1883.
17.
StagnaroCd'AscanioAParmaAContiUEmdinMDellaRossa Aet al.Might troponin be a marker for subclinical scleroderma heart involvement (SHI)? [abstract]. Arthritis Rheumatol2015;67(Suppl 10) Abstract 2965.
18.
Hoffmann-VoldAMMidtvedtOGarenTLundMBAndreassenAMolberg. Assessment of NT-Pro BNP as a potential marker for pulmonary hypertension in systemic sclerosis: data from a large, prospective and unselected patient cohort [abstract]. Arthritis Rheumatol2015;67(Suppl 10) Abstract 2990.
19.
TerrierBGouyaHBerezneARegentACohenPGuillevinLet al.Impact of cardiac magnetic resonance imaging with t1 mapping and multi-b value diffusion-weighted sequences in systemic sclerosis for the assessment of myocardial microscopic fibrosis and perfusion [abstract]. Arthritis Rheumatol2015;67(Suppl 10) Abstract 1892.
20.
HakamiNJohnsonSRDeep Vein Thrombosis and pulmonary embolism in systemic sclerois [abstract]. Arthritis Rheumatol2015;67(Suppl 10) Abstract 1875.
21.
Hoffmann-VoldAMHeiervang TennøeAMidtvedtOGarenTLundMBAalokkenTMet al.High levels of CCL-18 are associated with deterioration of lung function, increased annual fibrosis progression rate and decreased survival in systemic sclerosis [abstract]. Arthritis Rheumatol2015;67(Suppl 10) Abstract 1077.
22.
PrasseAProbstCBargagliEZisselGToewsGBFlahertyKRet al.Serum CC-chemokine ligand 18 concentration predicts outcome in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med2009;179(8):717–23
23.
LazzaroniMGColomboECavazzanaIDistlerODobrotaREisenringJet al.Increased frequency of malignancies synchronous to the onset of systemic sclerosis in anti-rna polymerase iii antibodies positive patients: a Eustar Multicentre Study [abstract]. Arthritis Rheumatol2015;67(Suppl 10) Abstract 3260.
24.
SakrLYounanianEHudsonMWangMBaronMBernatskySSystemic sclerosis and lung cancer risk: data from the Canadian Scleroderma Research group [abstract]. Arthritis Rheumatol2015;67(Suppl 10) Abstract 1902.
25.
ClementsPJTashkinDRothMKhannaDFurstDETsengCHet al.The Scleroderma Lung Study II (SLS II) shows that both oral cyclophosphamide (cyc) and mycophenolate mofitil (mmf) are efficacious in treating progressive interstitial lung disease (ild) in patients with systemic sclerosis (SSc) [abstract]. Arthritis Rheumatol2015;67(Suppl 10) Abstract 1075.
26.
VolkmannERRothMElashoffRClementsPJFurstDEKhannaDet al.Safety and tolerability of cyclophosphamide versus mycophenolate for systemic sclerosis-related interstitial lung disease [abstract]. Arthritis Rheumatol2015;67(Suppl 10) Abstract 1076.
27.
DentonCPCoghlanJGGhofraniHAGrimmingerFHeJRiemekastenGet al.Efficacy and safety of riociguat in patients with pulmonary arterial hypertension (pah) associated with connective tissue disease (ctd) [abstract]. Arthritis Rheumatol2015;67(Suppl 10) Abstract 3079.
